Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Evomela Generic Name & Formulations
Legal Class
Rx
General Description
Melphalan HCl 50mg/vial; lyophilized pwd; for IV infusion after reconstitution.
Pharmacological Class
Alkylating agent.
How Supplied
Single-dose vial (20mL)—1
Manufacturer
Generic Availability
NO
Evomela Indications
Indications
High-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma.
Evomela Dosage and Administration
Adult
Give prophylactic antiemetics. Give by IV infusion over 30mins. 100mg/m2 daily for 2 consecutive days (Days -3 and -2) prior to transplantation (Day 0). If patient weighs >130% of their ideal body weight, use adjusted ideal body weight.
Children
Not established.
Evomela Contraindications
Not Applicable
Evomela Boxed Warnings
Boxed Warning
Severe bone marrow suppression. Hypersensitivity. Leukemogenicity.
Evomela Warnings/Precautions
Warnings/Precautions
Bone marrow suppression. Monitor CBCs, provide supportive care for infections, anemia, thrombocytopenia until adequate recovery. GI toxicity; provide supportive care. Monitor LFTs. Renal impairment. Embryo-fetal toxicity. Advise to use effective contraception during and for 6 months (females of reproductive potential) or for 3 months (males w. female partners) after the last dose. Pregnancy. Nursing mothers: not recommended (during and for 1 week after the last dose).
Evomela Pharmacokinetics
See Literature
Evomela Interactions
Interactions
Caution with cyclosporine, BCNU.
Evomela Adverse Reactions
Adverse Reactions
Decreased neutrophil, WBC, lymphocyte, and platelet counts, diarrhea, nausea, fatigue, hypokalemia, anemia, vomiting; mucositis, hypersensitivity reactions, hepatic disorders, secondary malignancies, infertility.
Evomela Clinical Trials
See Literature
Evomela Note
Not Applicable
Evomela Patient Counseling
See Literature
